M. Caroli Costantini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. Caroli Costantini has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Cartocci
Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy
1 shared publication Alessia D'IGnazio
Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy
1 shared publication- Alfonso Sagnella
Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università degli studi di Siena, Siena, Italia
1 shared publication - Carlotta Marzocchi
Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy
1 shared publication Daniele Marrelli
Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy
1 shared publication- Federica Petrelli
USL Northwest Tuscany, “Monterosso” Polyspecialistic Center, Pathology Unit
1 shared publication
Latest Publications
- 1 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (3) , 561-569
Signet ring cell percentage in poorly cohesive gastric cancer patients: A potential novel predictor of survival
- 1 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (3) , 561-569
Signet ring cell percentage in poorly cohesive gastric cancer patients: A potential novel predictor of survival
- Open Access
- 4 August 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (2) , 369-378
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a “surgical” and a “cytological” series
Purpose: Pregnancy-associated plasma protein A (PAPPA) is a metalloproteinase initially described for its role during pregnancy. PAPPA regulates IGF ligands 1 (IGF1) bioavailability through the degradation of IGF-binding protein 4 (IGFBP4). After the cleavage of IGFBP4, free IGF1 is able to bind IGF1 receptors (IGF1R) triggering the downstream signaling. Recently, PAPPA expression has been linked with development of several cancers. No data have been published on thyroid cancer, yet. Methods: We evaluated PAPPA, insulin-like growth factor (IGF1), IGF1 receptors (IGF1R) and IGF-binding protein 4 (IGFBP4) mRNA expression levels in a “Surgical series” of 94 thyroid nodules (64 cancers, 16 follicular adenomas and 14 hyperplastic nodules) and in a “Cytological series” of 80 nodules from 74 patients underwent to fine-needle aspiration cytology (FNAC). In tissues, PAPPA was also evaluated by western blot. Results: We found that PAPPA expression was increased in thyroid cancer specimen at mRNA and protein levels and that, adenomas and hyperplastic nodules had an expression similar to normal tissues. When applied on thyroid cytologies, PAPPA expression was able to discriminate benign from malignant nodules contributing to pre-surgical classification of the nodules. We calculated a cut-off with a good specificity (91%) which reached 100% when combined with molecular biology. Conclusion: These results show that PAPPA could represent a promising diagnostic marker for differentiated thyroid cancer.
- 4 August 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (2) , 369-378
Open AccessPregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a “surgical” and a “cytological” series
Purpose: Pregnancy-associated plasma protein A (PAPPA) is a metalloproteinase initially described for its role during pregnancy. PAPPA regulates IGF ligands 1 (IGF1) bioavailability through the degradation of IGF-binding protein 4 (IGFBP4). After the cleavage of IGFBP4, free IGF1 is able to bind IGF1 receptors (IGF1R) triggering the downstream signaling. Recently, PAPPA expression has been linked with development of several cancers. No data have been published on thyroid cancer, yet. Methods: We evaluated PAPPA, insulin-like growth factor (IGF1), IGF1 receptors (IGF1R) and IGF-binding protein 4 (IGFBP4) mRNA expression levels in a “Surgical series” of 94 thyroid nodules (64 cancers, 16 follicular adenomas and 14 hyperplastic nodules) and in a “Cytological series” of 80 nodules from 74 patients underwent to fine-needle aspiration cytology (FNAC). In tissues, PAPPA was also evaluated by western blot. Results: We found that PAPPA expression was increased in thyroid cancer specimen at mRNA and protein levels and that, adenomas and hyperplastic nodules had an expression similar to normal tissues. When applied on thyroid cytologies, PAPPA expression was able to discriminate benign from malignant nodules contributing to pre-surgical classification of the nodules. We calculated a cut-off with a good specificity (91%) which reached 100% when combined with molecular biology. Conclusion: These results show that PAPPA could represent a promising diagnostic marker for differentiated thyroid cancer.